119 related articles for article (PubMed ID: 9247305)
1. Differential expression of p16INK4a and p16beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations.
Rizos H; Becker TM; Holland EA; Kefford RF; Mann GJ
Oncogene; 1997 Jul; 15(5):515-23. PubMed ID: 9247305
[TBL] [Abstract][Full Text] [Related]
2. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.
Liu L; Lassam NJ; Slingerland JM; Bailey D; Cole D; Jenkins R; Hogg D
Oncogene; 1995 Jul; 11(2):405-12. PubMed ID: 7624155
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
[TBL] [Abstract][Full Text] [Related]
4. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
[TBL] [Abstract][Full Text] [Related]
5. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.
Liu L; Goldstein AM; Tucker MA; Brill H; Gruis NA; Hogg D; Lassam NJ
Genes Chromosomes Cancer; 1997 May; 19(1):52-4. PubMed ID: 9135995
[TBL] [Abstract][Full Text] [Related]
6. Germline splicing mutations of CDKN2A predispose to melanoma.
Loo JC; Liu L; Hao A; Gao L; Agatep R; Shennan M; Summers A; Goldstein AM; Tucker MA; Deters C; Fusaro R; Blazer K; Weitzel J; Lassam N; Lynch H; Hogg D
Oncogene; 2003 Sep; 22(41):6387-94. PubMed ID: 14508519
[TBL] [Abstract][Full Text] [Related]
7. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Flores JF; Walker GJ; Glendening JM; Haluska FG; Castresana JS; Rubio MP; Pastorfide GC; Boyer LA; Kao WH; Bulyk ML; Barnhill RL; Hayward NK; Housman DE; Fountain JW
Cancer Res; 1996 Nov; 56(21):5023-32. PubMed ID: 8895759
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
Kamb A; Shattuck-Eidens D; Eeles R; Liu Q; Gruis NA; Ding W; Hussey C; Tran T; Miki Y; Weaver-Feldhaus J
Nat Genet; 1994 Sep; 8(1):23-6. PubMed ID: 7987388
[TBL] [Abstract][Full Text] [Related]
9. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.
Fujimoto A; Morita R; Hatta N; Takehara K; Takata M
Oncogene; 1999 Apr; 18(15):2527-32. PubMed ID: 10229204
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.
Liu L; Dilworth D; Gao L; Monzon J; Summers A; Lassam N; Hogg D
Nat Genet; 1999 Jan; 21(1):128-32. PubMed ID: 9916806
[TBL] [Abstract][Full Text] [Related]
11. Mutation analysis of the CDKN2A promoter in Australian melanoma families.
Pollock PM; Stark MS; Palmer JM; Walters MK; Aitken JF; Martin NG; Hayward NK
Genes Chromosomes Cancer; 2001 Sep; 32(1):89-94. PubMed ID: 11477665
[TBL] [Abstract][Full Text] [Related]
12. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
[TBL] [Abstract][Full Text] [Related]
13. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
Bahuau M; Vidaud D; Jenkins RB; Bièche I; Kimmel DW; Assouline B; Smith JS; Alderete B; Cayuela JM; Harpey JP; Caille B; Vidaud M
Cancer Res; 1998 Jun; 58(11):2298-303. PubMed ID: 9622062
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
15. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.
Levanat S; Situm M; Crnić I; Marasović D; Puizina-Ivić N; Pokupcić N; Musani V; Komar A; Kubat M; Furac I; Karija-Vlahović M; Krizanac S
Croat Med J; 2003 Aug; 44(4):418-24. PubMed ID: 12950144
[TBL] [Abstract][Full Text] [Related]
16. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
Yakobson E; Eisenberg S; Isacson R; Halle D; Levy-Lahad E; Catane R; Safro M; Sobolev V; Huot T; Peters G; Ruiz A; Malvehy J; Puig S; Chompret A; Avril MF; Shafir R; Peretz H; Bressac-de Paillerets B
Eur J Hum Genet; 2003 Apr; 11(4):288-96. PubMed ID: 12700603
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds.
Holland EA; Beaton SC; Becker TM; Grulet OM; Peters BA; Rizos H; Kefford RF; Mann GJ
Oncogene; 1995 Dec; 11(11):2289-94. PubMed ID: 8570179
[TBL] [Abstract][Full Text] [Related]
18. A novel p16INK4A transcript.
Mao L; Merlo A; Bedi G; Shapiro GI; Edwards CD; Rollins BJ; Sidransky D
Cancer Res; 1995 Jul; 55(14):2995-7. PubMed ID: 7541708
[TBL] [Abstract][Full Text] [Related]
19. Hereditary cutaneous melanoma.
Platz A; Ringborg U; Hansson J
Semin Cancer Biol; 2000 Aug; 10(4):319-26. PubMed ID: 10966854
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
